title: Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives.
abstract: We have studied the in vitro effects of nucleoside inhibitors of reverse transcriptase on bone marrow myeloid and erythroid progenitor development. Both 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC) potently inhibited in vitro haematopoiesis, while 2',3'-dideoxyadenosine (DDA) was less inhibitory in this culture system. Studies of candidate antiretroviral agents in bone marrow culture may predict clinical toxicity as well as lead to strategies for combination therapy which minimize impairment of haematopoiesis.
authors.affiliation: Department of Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, Mass. 02215.
authors.forename: M
authors.initials: M
authors.lastname: Johnson
authors.forename: T
authors.initials: T
authors.lastname: Caiazzo
authors.forename: J M
authors.initials: JM
authors.lastname: Molina
authors.forename: R
authors.initials: R
authors.lastname: Donahue
authors.forename: J
authors.initials: J
authors.lastname: Groopman
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000503:physiopathology; D001853:Bone Marrow / Q000187:drug effects*; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D003864:Depression, Chemical; D015224:Dideoxynucleosides / Q000494:pharmacology*; D004920:Erythropoiesis / Q000187:drug effects*; D006801:Humans; D016047:Zalcitabine; D015215:Zidovudine / Q000494:pharmacology*
chemical_list: D015224:Dideoxynucleosides; D015215:Zidovudine; D016047:Zalcitabine